ProCE Banner Activity

HPTN 084 Update: Long-Acting Injectable CAB vs Daily Oral TDF/FTC for HIV PrEP in Cisgender Women

Slideset Download
Conference Coverage
An additional 1 year of unblinded follow-up of the HPTN 084 study continues to support superiority of long-acting injectable CAB vs daily oral TDF/FTC in reducing incident HIV infection among cisgender women at high risk.

Released: August 03, 2022

Expiration: August 02, 2023

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare


IAS 2021

ProCE Banner